Skip to main content
CRS 2026 Annual Meeting & Exposition Main banner
Rate ePoster

Nanomedicine and Nanoscale Delivery (Focus Group – NND)

Immunogenic cell death in glioblastoma via lipid nanoparticle co-delivery of chemotherapy and siRNA

Hend Abdelbar – Professor, King's College London; Khuloud Al-Jamal – Professor of Drug Delivery & Nanomedicine, King's College London; Osama Hassuneh – PhD student, Hong Kong University; Victor Moreno-Zafra – Postdoctoral associate, King's College London; Nadia Rouatbi – PhD, King's College London; Julie Tzu-Wen Wang – Postdoctoral associate, King's College London; Adam Walters – Lecturer, King's College London; Alla Zam – PhD student, King's College London
Introduction:

Glioblastoma (GBM) is a highly aggressive primary brain tumour with poor prognosis and limited therapeutic options [1,2]. Immunotherapy offers new opportunities, but efficacy is hindered by the immunosuppressive brain tumour microenvironment [3,4]. Immunogenic cell death (ICD) can convert tumours into in situ vaccines by releasing danger-associated molecular patterns that stimulate anti-tumour immunity [5]. Lipid nanoparticles (LNPs) provide a versatile platform for co-delivering chemotherapeutics and siRNA to modulate tumour immunity. Here, we investigate ICD induction in GBM and its immunological consequences via LNP-based co-delivery of chemotherapy and CD47-targeting siRNA.

Learning Objectives:

  • Understand that different drugs have different requirements for loading into LNPs.
  • Explain how dual-payload LNPs influence drug-specific therapeutic outcomes in glioblastoma.
  • Evaluate strategies to exploit immunogenic cell death in the brain to enhance anti-tumour immune responses.